GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA review

GSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion.

The deal gives GSK control of Nuvalent’s two experimental lung-cancer therapies, both currently undergoing FDA review with decisions expected later this year.

If approved, the medicines would expand GSK’s oncology pipeline and represent one of the largest biotech purchases in the company’s history.